Loading stock data…
Loading stock data…
US$2.16
Get one email when CVKD crosses your level. Checked every 15 minutes during market hours.
▼ -0.17 (-7.30%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
27.5
OversoldAbove 70 can signal overbought; below 30, oversold.
MACD
-0.46
Bearish momentumMACD below its signal line (-0.42).
50-day average
4.01
Price belowShort-term trend reference.
200-day average
7.47
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a phase 3-ready, first-in-class 12-LOX inhibitor designed to treat heparin-induced thrombocytopenia (HIT), a severe immune-mediated thrombotic disorder, by targeting the primary underlying immune mechanisms unlike existing treatments that only address complications. CAD-1005 has received Orphan Drug and Fa…
www.cadrenal.com2 strong buy · 5 buy · 1 hold · 0 sell · 0 strong sell (8 analysts, 2026-07-01)
2 strong buy · 5 buy · 1 hold · 0 sell · 0 strong sell (8 analysts, 2026-06-01)
2 strong buy · 5 buy · 1 hold · 0 sell · 0 strong sell (8 analysts, 2026-05-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-07-01 | 0.8 | 0.95 | ✓ Beat |
| 2026-05-07 | -1.57 | -1.04 | ✓ Beat |
| 2026-04-28 | 4.82 | 4.97 | ✓ Beat |
| 2026-03-27 | -3.78 | -0.97 | ✓ Beat |
| 2026-02-10 | 0.96 | 1 | ✓ Beat |
| 2025-12-09 | 0.18 | 0.38 | ✓ Beat |
| 2025-11-10 | -1.55 | -1.31 | ✓ Beat |
Companies in the same industry, via Finnhub